Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection
S Chou, K Song, J Wu, T Bo… - The Journal of infectious …, 2022 - academic.oup.com
Background In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …
[HTML][HTML] Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection
S Chou, J Wu, K Song, T Bo - Antiviral research, 2019 - Elsevier
In a Phase 2 clinical trial, 120 subjects with cytomegalovirus (CMV) infection refractory or
resistant to standard therapy were randomized equally to 3 doses of oral maribavir …
resistant to standard therapy were randomized equally to 3 doses of oral maribavir …
Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients
S Chou, S Alain, C Cervera, RF Chemaly… - The Journal of …, 2024 - academic.oup.com
Background This drug resistance analysis of a randomized trial includes 234 patients
receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where …
receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where …
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
S Chou, M Hakki, S Villano - Antiviral research, 2012 - Elsevier
Resistance to the experimental human cytomegalovirus (CMV) UL97 kinase inhibitor
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
A Schubert, K Ehlert, S Schuler-Luettmann… - BMC infectious …, 2013 - Springer
Background Human cytomegalovirus infections are still significant causes of morbidity and
mortality in transplant recipients. The use of antiviral agents is limited by toxicity and …
mortality in transplant recipients. The use of antiviral agents is limited by toxicity and …
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
WL Drew, RC Miner, GI Marousek, S Chou - Journal of clinical virology, 2006 - Elsevier
BACKGROUND: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind …
GA Papanicolaou, FP Silveira… - Clinical Infectious …, 2019 - academic.oup.com
Background Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to
available antivirals ([val] ganciclovir, foscarnet, cidofovir) are associated with higher mortality …
available antivirals ([val] ganciclovir, foscarnet, cidofovir) are associated with higher mortality …
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance
S Chou, LC Van Wechel… - The Journal of infectious …, 2007 - academic.oup.com
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical
antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV …
antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV …
Maribavir: Mechanism of action, clinical, and translational science
K Sun, M Fournier, AK Sundberg… - Clinical and …, 2024 - Wiley Online Library
Maribavir is an oral benzimidazole riboside for treatment of post‐transplant cytomegalovirus
(CMV) infection/disease that is refractory to prior antiviral treatment (with or without …
(CMV) infection/disease that is refractory to prior antiviral treatment (with or without …
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir
S Chou - Antimicrobial agents and chemotherapy, 2009 - Am Soc Microbiol
In vitro resistance to maribavir (MBV), a cytomegalovirus UL97 kinase inhibitor currently in
clinical trials, is known to result from viral UL97 mutations that confer moderate to high-level …
clinical trials, is known to result from viral UL97 mutations that confer moderate to high-level …
相关搜索
- maribavir for treatment cytomegalovirus infection
- drug resistance cytomegalovirus infection
- maribavir for treatment associated phenotypes
- associated phenotypes cytomegalovirus infection
- drug exposure maribavir susceptibility
- cytomegalovirus infections hematopoietic cell
- cytomegalovirus infections transplant recipients
- drug resistance transplant recipients